Global Market Outlook on Ibuprofen

  • Ibuprofen prices have increased by 22 percent over the past one year * driven by the increase in raw material cost
  • Prices for Isobutyl Benzene have increased by 11 percent
  • Aluminium chloride** prices increased by 4 percent in 2016 after consistently declining for the past two years
  • Sodium metal prices increased by 5 percent over the past one year
  • Additionally SI group increased its Ibuprofen price by 40 percent (in June 2016), however such an increase is currently not reflected by the rest of the market**.

Total market for Ibuprofen is currently estimated to be about 43,000 MT in 2017 and growing at a CAGR of 2 percentShasun is the market leader with about 16 percent market share, whereas, IOLCP holds the maximum capacity of 7200 MT

  • Average utilization for the top six players is currently about 90 percent with Granules operating at full capacity
  • SI group and IOLCP have the lowest utilization rates among the top six players
  • BASF and IOLCP are the only two players expanding capacity for Ibuprofen. BASF has announced capacity expansion for Ibuprofen at its Texas, US and Ludwigshafen, Germany sites which are expected to be operational by 2018 and 2021 whereas IOLCP has expanded its capacity to 7200 in 2017, from 6200 in 2015
  • Vinati Organics leads the raw material (Isobutyl Benzene-IBB) supply globally, and is planning to increase its capacity to 25000 MT
  • •Additionally, Vinati also plans to invest in new capacity for Isobutylacetophenone -IBAP (advance intermediate of Ibuprofen) which could be used as an alternate to sourcing IBB by Ibuprofen manufacturers

Ibuprofen - Industry Utilization and Capacity Expansions

  • Average utilization for the top six players is currently about 90 percent
  • Granules Biocause is currently operating at full capacity, however does not have any planned capacity expansions until 2018
  • SI group and IOLCP have the lowest utilization rates among the top six players
  • BASF is planning to expand its capacity for Ibuprofen at its Ludwigshafen, Germany and Texas, US sites with a total investment of USD 227.6 million
  • German plant is expected to be operational by 2021 , while the US plant is expected to be operational by 2018
  • IOLCP has increased its Ibuprofen capacity (India) to 7200 MT in 2017 from 6200 MT in 2015
  • Granules’ current and estimated capacity for 2018 is 4800 MT